dual gip/glp-1 receptor agonist The Sustained Effects of a Agonist, NNC0090-2746, in Patients with Type 2 Diabetes The Emerging Role of Dual
Description
Structure Therapeutics announces positive results from phase 1b clinical study of oral GLP-1 receptor agonist GSBR-1290 and provides program update(2023)
It attained FDA approval in 2016 for the management of T2D
Thats a significantly higher percentage than most other non-surgical weight loss treatments
Skov J, Dejgaard A, Frkir J, et al
In an animal study, using a mouse model with different age groups, non-alcoholic steatohepatitis (NASH) was induced, revealing age-dependent effects on cardiac function
